COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
Laia Garrigós(Hospital Universitario Dexeus), Maria Belen Delany(Althaia), Myria Galazi(Bank of Cyprus Oncology Center), Clara Martínez-Vila(Althaia), Mieke Van Hemelrijck(Ghent University Hospital), Barbara Pistilli(Institut Gustave Roussy), E. Colomba-Blameble(Institut Gustave Roussy), Chiara Saggia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Eudald Felip(University of Ioannina), Rossana Berardi(Marche Polytechnic University), Daniele Generali(University of Trieste), Rachel Sharkey(Chelsea and Westminster Hospital), Francesca Mazzoni(Azienda Ospedaliero-Universitaria Careggi), Diego Ottaviani(Royal London Hospital), John Chester(Velindre Cancer Centre), Gemma Viñas(Institut Català d'Oncologia), Sònia Pernas, Alberto Zambelli, Rachel Wuerstlein(LMU Klinikum), Alexia Bertuzzi(Humanitas University), Michela Libertini(Fondazione Poliambulanza Istituto Ospedaliero), Thomas Newsom-Davis(Chelsea and Westminster Hospital), Isabel Ruíz-Camps(Universitat Autònoma de Barcelona), Ana Sánchez(Research Institute Hospital 12 de Octubre), Lorenzo Chiudinelli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Annalisa Guida(Azienda Ospedaliera S.Maria), Uma Mukherjee(University College London Hospitals NHS Foundation Trust), Marta Matas(Althaia), Federica Zoratto(Ospedale Santa Maria Goretti), Alessio Cortellini(Campus Bio Medico University Hospital), Ailsa Lumsden(King's College London), Mark Bower(Chelsea and Westminster Hospital), Mar Marín(King's College London), Nikolaos Diamantis(Hammersmith Hospital), Marta Betti(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Carla Strina(Istituti Ospitalieri di Cremona), Lucia Del Mastro(Ospedale Policlinico San Martino), Bruno Vincenzi(Campus Bio Medico University Hospital), Eva Ciruelos(Hospital Universitario 12 De Octubre), Cristina Saura(Vall d'Hebron Hospital Universitari), Matteo Lambertini(Ospedale Policlinico San Martino), Angela Loizidou(Université Libre de Bruxelles), María Iglesias(Hospital Son Llatzer), Helena Pla(Institut Català d'Oncologia), Aleix Prat(Hospital Clínic de Barcelona), Elia Seguí, Giampiero Porzio(San Salvatore Hospital), Gianpiero Rizzo(Policlinico San Matteo Fondazione), Armando Santoro(IRCCS Humanitas Research Hospital), Ylenia Perone(Royal Free London NHS Foundation Trust)
Cited by 7
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k